注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Glaukos Corp是一家眼科医疗技术和制药公司。该公司专注于开发治疗青光眼、角膜疾病和视网膜疾病的新疗法。其候选产品包括微创青光眼手术(MIGS)产品,其中包括插入微型装置或药物输送系统,旨在通过恢复青光眼和MIGS患者的自然房水流出途径来降低眼内压(IOP)测量眼内压力的生物传感器;为受角膜扩张障碍(如圆锥角膜或屈光障碍)影响的患者强化、稳定和重塑角膜的生物活性药物;适用于眼睑并设计用于治疗干眼症、老花眼、青光眼和其他眼表疾病和病症的透皮药物;微创、生物可腐蚀的缓释药物输送植入物,以改善患者的视力。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Thomas W. Samuelson | - | - | Member of Scientific Advisory Board |
Richard L. Lindstrom | 74 | - | Member of Scientific Advisory Board |
Gilbert H. Kliman | 63 | 2020 | Independent Director |
Ike K. Ahmed | - | - | Member of Scientific Advisory Board |
Kerry D. Solomon | - | - | Member of Scientific Advisory Board |
Richard A. Lewis | - | - | Member of Scientific Advisory Board |
Eric D. Donnenfeld | 66 | - | Member of Scientific Advisory Board |
Edward J. Holland | - | - | Member of Scientific Advisory Board |
Leana S. Wen | 39 | 2021 | Independent Director |
Mark J. Foley | 57 | 2014 | Lead Independent Director |
Denice M. Torres | 62 | 2021 | Independent Director |
Kuldev Singh | - | - | Member of Scientific Advisory Board |
John Berdahl | - | - | Member of Scientific Advisory Board |
Robert J. Cionni | - | - | Member of Scientific Advisory Board |
Aimee S. Weisner | 53 | 2014 | Independent Director |
Thomas William Burns | 61 | 2002 | Chairman & CEO |
Marc A. Stapley | 53 | 2014 | Independent Director |
David Frank Hoffmeister | 68 | 2014 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核